Phase III data shows Lyxumia (Sanofi) reduces blood glucose levels in Type 2 Diabetes patients

New Phase III data shows Lyxumia (lixisenatide), from Sanofi, has a positive effect on blood glucose levels in patients with Type 2 Diabetes. The pooled analysis included data of 753 patients from three randomized studies of either once-daily lixisenatide plus standard of care versus placebo plus standard of care, to quantify the effects on blood glucose levels. After 24 weeks of treatment, the change to average blood sugar levels for the past two to three months was -0.77% with lixisenatide compared with -0.29% with placebo.

The three studies included in this analysis were GetGoal-L, GetGoal-L Asia and GetGoal Duo1. The most common adverse events were nausea, vomiting, diarrhea and symptomatic hypoglycemia. Data was presented at the American Diabetes Association 73rd Scientific Sessions.